APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists for Vasomotor Symptoms

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms include Astellas Pharma and Bayer etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neurokinin Receptor Antagonists for Vasomotor Symptoms, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, also provides the sales of main regions and countries. Of the upcoming market potential for Neurokinin Receptor Antagonists for Vasomotor Symptoms, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, projected growth trends, production technology, application and end-user industry.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Company

Astellas Pharma

Bayer

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant

Elinzanetant

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic

Pharmacy

Other

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neurokinin Receptor Antagonists for Vasomotor Symptoms in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fezolinetant Major Manufacturers Table 3. Elinzanetant Major Manufacturers Table 4. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital and Clinic Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends Table 9. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers Table 10. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges Table 11. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints Table 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2026) Table 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2027-2032) Table 17. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units) Table 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032) & (K Units) Table 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2026) Table 21. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2027-2032) Table 22. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Manufacturers (2021-2026) Table 26. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers, Product Type & Application Table 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2026) Table 37. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2027-2032) Table 38. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 40. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 41. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026) Table 42. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2027-2032) Table 43. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2026) & (US$/Unit) Table 44. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2027-2032) & (US$/Unit) Table 45. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2026) Table 49. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2027-2032) Table 50. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 52. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 53. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026) Table 54. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2027-2032) Table 55. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2026) & (US$/Unit) Table 56. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2027-2032) & (US$/Unit) Table 57. Astellas Pharma Company Information Table 58. Astellas Pharma Business Overview Table 59. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 61. Astellas Pharma Recent Development Table 62. Bayer Company Information Table 63. Bayer Business Overview Table 64. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 66. Bayer Recent Development Table 67. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 70. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 71. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2021-2026) & (US$/Unit) Table 72. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2027-2032) & (US$/Unit) Table 73. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 74. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 75. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 76. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 77. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2021-2026) & (US$/Unit) Table 78. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2027-2032) & (US$/Unit) Table 79. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 81. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 82. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 83. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 84. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 85. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2021-2026) & (US$/Unit) Table 86. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2027-2032) & (US$/Unit) Table 87. United States Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 88. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 89. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 90. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 93. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 94. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2021-2026) & (US$/Unit) Table 95. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2027-2032) & (US$/Unit) Table 96. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 99. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 100. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2021-2026) & (US$/Unit) Table 101. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2027-2032) & (US$/Unit) Table 102. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 104. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 105. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 106. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 107. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 108. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2021-2026) & (US$/Unit) Table 109. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2027-2032) & (US$/Unit) Table 110. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 111. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 112. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 113. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 114. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 115. Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 116. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 117. Switzerland Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 118. Sweden Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 119. Poland Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 120. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 121. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 122. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 123. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 124. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2021-2026) & (US$/Unit) Table 125. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2027-2032) & (US$/Unit) Table 126. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 127. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 128. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 129. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 130. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2021-2026) & (US$/Unit) Table 131. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2027-2032) & (US$/Unit) Table 132. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 135. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 136. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2021-2026) & (US$/Unit) Table 137. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2027-2032) & (US$/Unit) Table 138. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 139. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 141. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 142. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2021-2026) & (US$/Unit) Table 143. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2027-2032) & (US$/Unit) Table 144. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 146. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 147. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 148. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 149. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 150. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2021-2026) & (US$/Unit) Table 151. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2027-2032) & (US$/Unit) Table 152. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 153. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 154. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 155. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 156. Taiwan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 157. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 158. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 159. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 160. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 161. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 162. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2021-2026) & (US$/Unit) Table 163. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Type (2027-2032) & (US$/Unit) Table 164. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 167. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 168. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2021-2026) & (US$/Unit) Table 169. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Application (2027-2032) & (US$/Unit) Table 170. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 175. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 176. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2021-2026) & (US$/Unit) Table 177. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Country (2027-2032) & (US$/Unit) Table 178. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 179. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 180. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 181. Colombia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 182. Peru Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 183. Saudi Arabia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 184. Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 185. UAE Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 186. Turkey Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 187. Iran Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 188. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Table 189. Key Raw Materials Table 190. Raw Materials Key Suppliers Table 191. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List Table 192. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers List Table 193. Research Programs/Design for This Report Table 194. Authors List of This Report Table 195. Secondary Sources Table 196. Primary Sources List of Figures Figure 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Image Figure 2. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fezolinetant Image Figure 5. Elinzanetant Image Figure 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital and Clinic Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2032) & (US$ Million) Figure 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2032) Figure 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032) & (K Units) Figure 17. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales YoY (2021-2032) & (K Units) Figure 20. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales YoY (2021-2032) & (K Units) Figure 21. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales YoY (2021-2032) & (K Units) Figure 24. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032) Figure 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032) Figure 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032) Figure 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032) Figure 39. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Type (2021-2032) Figure 40. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Type (2021-2032) Figure 41. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Application (2021-2032) Figure 42. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Application (2021-2032) Figure 43. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country (2021-2032) Figure 44. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country (2021-2032) Figure 45. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Type (2021-2032) Figure 46. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Type (2021-2032) Figure 47. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Application (2021-2032) Figure 48. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Application (2021-2032) Figure 49. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country (2021-2032) Figure 50. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country (2021-2032) Figure 51. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Type (2021-2032) Figure 52. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Type (2021-2032) Figure 53. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Application (2021-2032) Figure 54. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Application (2021-2032) Figure 55. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Type (2021-2032) Figure 56. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Type (2021-2032) Figure 57. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Application (2021-2032) Figure 58. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Application (2021-2032) Figure 59. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country (2021-2032) Figure 60. Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country (2021-2032) Figure 61. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Type (2021-2032) Figure 62. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Type (2021-2032) Figure 63. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Application (2021-2032) Figure 64. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Application (2021-2032) Figure 65. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country (2021-2032) Figure 66. SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country (2021-2032) Figure 67. Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Fezolinetant
  • Elinzanetant
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Astellas Pharma
  • Bayer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
  3. 1.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fezolinetant
  5. 1.2.3 Elinzanetant
  6. 1.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
  7. 1.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital and Clinic
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Dynamics
  1. 2.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
  2. 2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
  3. 2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
  4. 2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region
  3. 3.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026)
  5. 3.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2027-2032)
  6. 3.2.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region
  9. 3.4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026)
  11. 3.4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032)
  12. 3.4.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers
  2. 4.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers
  6. 4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers, Product Type & Application
  13. 4.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market CR5 and HHI
  16. 4.8.2 2025 Neurokinin Receptor Antagonists for Vasomotor Symptoms Tier 1, Tier 2, and Tier 3
5 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
  1. 5.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type
  2. 5.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type
  6. 5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type
6 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
  1. 6.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application
  2. 6.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application
  6. 6.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application
7 Company Profiles
  1. 7.1 Astellas Pharma
  2. 7.1.1 Astellas Pharma Company Information
  3. 7.1.2 Astellas Pharma Business Overview
  4. 7.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  6. 7.1.5 Astellas Pharma Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  12. 7.2.5 Bayer Recent Developments
8 North America
  1. 8.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  2. 8.1.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  3. 8.1.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  4. 8.1.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
  5. 8.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 8.2.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  7. 8.2.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 8.2.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
  9. 8.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  10. 8.3.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  2. 9.1.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  4. 9.1.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
  5. 9.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 9.2.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 9.2.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
  9. 9.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  10. 9.3.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  2. 10.1.1 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  3. 10.1.2 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  4. 10.1.3 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
  5. 10.2 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 10.2.1 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  7. 10.2.2 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 10.2.3 China Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  2. 11.1.1 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  4. 11.1.3 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
  5. 11.2 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 11.2.1 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 11.2.3 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
  9. 11.3 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  10. 11.3.1 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  2. 12.1.1 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
  5. 12.2 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 12.2.1 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
  9. 12.3 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  10. 12.3.1 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
  2. 13.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process
  6. 13.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
  9. 13.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst